Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
HIV-1 infection is characterized by progressive depletion of CD4+ T cells that eventually
leads to clinically significant immunodeficiency. A chronic generalized immune activation is
now being recognized to be the main driving force for T cell depletion, loss of anti-HIV-1
immunity and disease progression during chronic HIV-1 infection. However, it is still unknown
whether reducing immune activation will restore CD4 T cell counts and leading to immune
reconstitution in chronic HIV infection. Mesenchymal stem cells (MSC) have been demonstrated
to decrease immune responses of the host, and can suppress inflammation in HIV-infected
non-responders. Here, the investigators propose a hypothesis that MSC can reduce immune
activation which subsequently lead to the restoration of CD4 T-cell counts dependent on dose
of transfused MSCs in HIV-infected patients.